药物筛选领域呼吁建立新标准

    2013年12月3日,在最新一期发表的Nature杂志中,蒙特利尔临床研究所的Benjamin Haibe-Kains博士表示,为了在药物筛选研究领域提高数据的可重复性,需要建立新的标准体系。他和他的团队成员分析了两项大规模的药物-基因组学研究数据(分别来自the Cancer Genome Project和the Cancer Cell Line Encyclopedia),并发现这两项研究中绝大部分数据结论是一致的,但是在药物敏感性检测上出现很大的偏差。保证数据的一致性对于鉴定新的治疗药物以及它们和现已处于临床应用的药物之间的潜在联合治疗策略均具有重要的意义。

    详细英文报道:

Writing in a recent issue of Nature, Dr. Benjamin Haibe-Kains of the Institut de Recherches Cliniques de Montréal says that additional standardization to improve the reproducibility of drug screening studies is needed. Haibe-Kains and his team analyzed the results of two large-scale pharmacogenomic studies--the Cancer Genome Project and the Cancer Cell Line Encyclopedia--and found that while most of the conclusions of the two studies were generally consistent, drug sensitivity measurements used in the two studies were highly inconsistent. Ensuring consistent data is important because it can help identify new therapeutic agents and their potential combinations with existing drugs to treat various diseases.

信息来源:http://www.bioon.com/industry/internation/587587.shtml